RenovoRx, Inc. (RNXT) company profile

RenovoRx, Inc. is a commercial-stage life sciences company that develops targeted oncology therapies and commercializes local drug-delivery medical devices. The company's core offering centers on its patented Trans-Arterial Micro-Perfusion therapy platform, enabled by its FDA-cleared RenovoCath catheter. This device delivers chemotherapeutic agents across arterial walls directly into solid tumors to bathe target tissue and minimize systemic toxicity. RenovoRx also investigates drug-device combination candidates, including intra-arterial gemcitabine delivery for locally advanced pancreatic cancer and bile duct cancer. Its primary customers include cancer treatment centers, hospitals, and high-volume National Cancer Institute-designated institutions.

The company focuses its commercialization activities in the United States, targeting high-volume treatment centers across the country. Commercial adoption includes 12 active cancer centers using its device, with an additional 21 centers evaluating or preparing for activation, totaling 33 institutions in its customer pipeline. RenovoRx maintains its principal executive offices and headquarters in Mountain View, California.

Summary of the business section of RenovoRx's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“We are offering 1,850,000 of units of securities (the “Units”) pursuant to this prospectus at an initial public offering price of $9.00 per Unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“We are a small company with 17 employees as of December 31, 2025.”